Document is current
Any future updates will be listed below
-
Authors
Yu, Xiaoqian
Tsuchiyagaito, Aki https://orcid.org/0000-0002-7606-1745
Misaki, Masaya https://orcid.org/0000-0002-6829-4311
Cochran, Gabe
Cohen, Zsofia P.
Singh, Manpreet K. https://orcid.org/0000-0002-4373-3293
Paulus, Martin P. https://orcid.org/0000-0002-0825-3606
Aupperle, Robin L.
Kirlic, Namik https://orcid.org/0000-0003-4153-8774
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (5P20GM121312)
- License Information
-
More Information
Article History
Received: 10 August 2024
Revised: 2 May 2025
Accepted: 16 June 2025
First Online: 13 July 2025
Competing interests
: MKS has received research support from the National Institutes of Health, the Patient Centered Outcomes Research Institute, the Brain and Behavior Foundation, Advanced Neuromodulation Systems, and AbbVie. She is on a data safety monitoring board for a study funded by the National Institute of Mental Health. She has in the past 3 years consulted for or been on an advisory board for AbbVie, Alkermes, Alto Neuroscience, Boehringer-Ingelheim, Johnson and Johnson, Karuna Therapeutics, Inc., Neumora, and Skyland Trail. She receives honoraria from the American Academy of Child and Adolescent Psychiatry and royalties from American Psychiatric Association Publishing and Thrive Global.
: The study was approved by Western Institutional Review Board and carried out in accordance with the principles of the Declaration of Helsinki and following institutional guidelines and regulations. All participants provided written informed consent.
